Global Cancer Monoclonal Antibodies Market:
Global cancer monoclonal antibodies market estimated to be valued US$ XX Mn in 2018 and poised to grow at CAGR of XX% over 2019-2025. Market for cancer monoclonal antibodies is projected to reach US$ XX Mn by 2025.
A monoclonal antibody drug in cancer treatments engages natural immune system functions to fight cancer. Cancer monoclonal antibodies may be used in combination with other cancer treatments. An antibody attaches itself to a specific molecule (antigen) on the surface of cancer cell when antibody binds to antigen, it acts as a flag to attract disease-fighting molecules or as a trigger that promotes the destruction of cancer cells by another immune system process. Due to its specificity, monoclonal antibodies have least adverse effects than other cancer treating drugs.
Get a Sample Copy of this Report @ https://www.alexareports.com/report-sample/170617
The market growth of cancer monoclonal antibodies is driven by increased prevalence of cancer worldwide. According to WHO, cancer is one of the leading cause of deaths worldwide. In 2012, there were around 14 Mn new cases of cancer, 8.2 Mn people died because of cancer and numbers of new cancer cases are projected to rise 70% in coming decades. In addition, monoclonal antibodies are proved to be having less adverse effects when compared to conventional non-targeted therapies. Increasing investment in the development of monoclonal antibodies, technological advancements that enabling the genetic sequencing and increasing specificity of the antibodies are fueling the sales revenue of cancer monoclonal antibodies market. However, the high cost of development, stringent regulatory guidelines, long period of clinical trials, are some of the factors hinder growth of cancer monoclonal antibodies market. Monoclonal antibodies are very specific in nature and have limited targets.
Cancer monoclonal antibodies market has been segmented based on application, type and conjugation, and distribution channel
Base on application, cancer monoclonal antibodies market is segmented into
Based on type of antibody, cancer monoclonal antibodies market is segmented into
Based on conjugation, cancer monoclonal antibodies market is segmented into
Antibody Directed Enzyme Prodrug Therapy(ADEPT)
Based on distribution channel, cancer monoclonal antibodies market segmented into
Grab amazing discount here @ https://www.alexareports.com/check-discount/170617
Currently cancer monoclonal antibodies market is witnessing a significant growth. The targeted and combination therapy drugs are leading in the market. Several market player collaborating to develop antibody drugs to treat various type of cancers. In January 2018, AbCellera Biologics, Inc. collaborated with Pfizer Inc. for new therapeutic antibody discovery. AbCellera will use its monoclonal antibody (mAb) screening techniques in the discovery of function modulating antibodies against undisclosed membrane protein targets. Academic institutions and organisations like National Institute of Health (USA), National Cancer Institute (USA) and many others are collaborating and participating in cancer research and awareness activities.
Geographically cancer monoclonal antibodies market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America cancer monoclonal antibodies market is growing at a steady rate due to increased prevalence of various cancers and higher acceptance of existing monoclonal antibodies among healthcare professionals in the region. According to National Cancer Institute (NIH), an estimated 1,685,210 new cases of cancer were diagnosed in the United States and 595,690 people will die from the disease in 2016. Asia-Pacific region is expected to exhibit rapid growth due to rise in government spending on healthcare infrastructure, increasing R&D spending by companies and growing patient and healthcare professional awareness in therapeutic use of monoclonal antibodies in treatment of cancer. For instance, Government-led fund providers, such as National Natural Science Foundation and National Basic Research Program of China, offer financial support to enterprises and universities to conduct monoclonal antibody research and development. The presence of healthcare regulations and procedures to promote early treatment of diseases using advanced therapeutics and public policies to support early screening and effective treatments for various cancers is driving the cancer monoclonal antibodies market in Latin-America.
Some of the players in cancer monoclonal antibodies market are Merck & Co. Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Spectrum Pharmaceuticals (U.S.), Eli Lilly and Company (U.S.), Amgen Inc. (U.S.), Bristol-Meyer Squibb (U.S.), Sanofi (France) and AstraZeneca (U.K.) to name a few.
To Enquire About This Comprehensive [email protected] https://www.alexareports.com/send-an-enquiry/170617
In May 2018, the U.S. Food and Drug Administration (FDA) granted accelerated approval to AstraZeneca’s durvalumab (IMFINZI) for the treatment of patients with locally advanced or metastatic urothelial carcinoma
In 2016, U.S Food and Drug Administration (FDA) approved Genentech Oncology’s tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer
Details of the market study:
- Historical Data: 2014 & 2017
- Base Year: 2018
- Forecasts: 2019-2025
- CAGR: 2019-2025
- Market trend analysis in terms of drivers, restraints and opportunities
- Industry analysis using Porter’s, PESTEL and SWOT
- Market estimates and forecasts available for the following regions and countries:
- North America (U.S. & Canada)
- Europe (UK & Germany)
- Asia Pacific (Japan & China)
- Latin America (Brazil, Mexico)
- MEA (South Africa)
- Market players analysis in terms of company’s overview, financial performance, product/service benchmarking and strategic initiatives taken up by them